November 8, 2024

Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel)

June 20, 2024

Neurotech Receives Priority Review of Biologics License Application (BLA) for NT-501 (revakinagene taroretcel) as a Treatment for Macular Telangiectasia Type 2 (MacTel)

January 1, 2024

Neurotech Executives Jim Mazzo, Chairman and Rich Small, CEO to Present at Annual J.P. Morgan Healthcare Conference

December 2, 2023

Rich Small, Chief Executive Officer, presents the latest on our Encapsulated Cell Therapy Platform during the Retina Innovation Showcase at OIS XIII Summit

September 13, 2023

Alex Gorsky Appointed to Neurotech’s Board as Lead Director

January 10, 2023

Neurotech Pharmaceuticals, Inc. Expands Executive Team with the Appointment of Scott Hunter as Chief Commercial Officer

November 2, 2022

Neurotech Pharmaceuticals Announces Positive Phase 3 Topline Results for NT-501 Implant in MacTel

October 24, 2022

Neurotech Chief Medical Officer authors article in Ophthalmology Times

A roadmap to preserving the prime years of patients diagnosed with MacTel, was published by Ophthalmology Times and written by Thomas Aaberg, Jr., explores the progression of MacTel and the… read more

July 20, 2022

Neurotech Chief Medical Officer authors article in The Ophthalmologist

The article, A Tiny Factory: Scaffolding a solution to macular telangiectasia with encapsulated cell therapy, was published by The Ophthalmologist and written by Thomas Aaberg, Jr., explores how ECT can… read more

October 31, 2021

News